NASDAQ:XOMA XOMA Royalty (XOMA) Stock Price, News & Analysis $37.60 +0.44 (+1.18%) Closing price 09/23/2025 04:00 PM EasternExtended Trading$37.66 +0.06 (+0.17%) As of 09/23/2025 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About XOMA Royalty Stock (NASDAQ:XOMA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get XOMA Royalty alerts:Sign Up Key Stats Today's Range$37.08▼$38.4850-Day Range$24.77▼$37.8652-Week Range$18.35▼$38.48Volume57,679 shsAverage Volume51,453 shsMarket Capitalization$454.51 millionP/E RatioN/ADividend YieldN/APrice Target$69.50Consensus RatingBuy Company Overview XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders. The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases. XOMA Royalty partners with biopharmaceutical companies across North America, Europe and other key markets, supporting the continued development and commercialization of innovative treatments. Its due-diligence process emphasizes assets with compelling clinical data, robust intellectual property protection and clear regulatory pathways. Led by a management team with extensive experience in pharmaceutical finance, licensing and royalty management, XOMA Royalty leverages industry relationships to source and structure transactions. The board comprises executives and advisors with backgrounds in drug development, investment banking and asset management, positioning the company to identify high-quality royalty opportunities and steward its growing portfolio over time.AI Generated. May Contain Errors. Read More XOMA Royalty Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks85th Percentile Overall ScoreXOMA MarketRank™: XOMA Royalty scored higher than 85% of companies evaluated by MarketBeat, and ranked 175th out of 946 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingBuy Consensus RatingXOMA Royalty has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Upside PotentialXOMA Royalty has a consensus price target of $69.50, representing about 84.8% upside from its current price of $37.60.Amount of Analyst CoverageXOMA Royalty has only been the subject of 1 research reports in the past 90 days.Read more about XOMA Royalty's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for XOMA Royalty are expected to grow in the coming year, from ($1.41) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of XOMA Royalty is -24.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of XOMA Royalty is -24.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXOMA Royalty has a P/B Ratio of 5.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about XOMA Royalty's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.41% of the float of XOMA Royalty has been sold short.Short Interest Ratio / Days to CoverXOMA Royalty has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in XOMA Royalty has recently decreased by 10.92%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXOMA Royalty does not currently pay a dividend.Dividend GrowthXOMA Royalty does not have a long track record of dividend growth. Sustainability and ESG3.0 / 5Environmental Score-0.22 Percentage of Shares Shorted2.41% of the float of XOMA Royalty has been sold short.Short Interest Ratio / Days to CoverXOMA Royalty has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in XOMA Royalty has recently decreased by 10.92%, indicating that investor sentiment is improving significantly. News and Social Media2.5 / 5News Sentiment0.52 News SentimentXOMA Royalty has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for XOMA Royalty this week, compared to 3 articles on an average week.MarketBeat Follows2 people have added XOMA Royalty to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, XOMA Royalty insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $155,837.00 in company stock.Percentage Held by InsidersOnly 7.20% of the stock of XOMA Royalty is held by insiders.Percentage Held by Institutions95.92% of the stock of XOMA Royalty is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about XOMA Royalty's insider trading history. Receive XOMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XOMA Royalty and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XOMA Stock News HeadlinesMural Oncology plc Publishes Definitive Proxy Statement for Acquisition by XOMA Royalty CorporationSeptember 23 at 8:11 PM | quiverquant.comQMural Oncology Plc Announces Acquisition by XOMA Royalty CorporationSeptember 23 at 6:10 PM | tipranks.comMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia. | The Oxford Club (Ad)Insider Sale: SVP of $XOMA Sells 15 SharesSeptember 23 at 5:51 PM | quiverquant.comQXoma Completes Acquisition of HilleVaxSeptember 23 at 5:51 PM | tipranks.comXOMA Royalty Declares Quarterly Preferred Stock DividendsSeptember 22 at 7:30 AM | globenewswire.comXoma announces closing of tender offer for HilleVaxSeptember 17, 2025 | msn.comHilleVax Acquired by XOMA, Delisting from NasdaqSeptember 17, 2025 | tipranks.comSee More Headlines XOMA Stock Analysis - Frequently Asked Questions How have XOMA shares performed this year? XOMA Royalty's stock was trading at $26.28 on January 1st, 2025. Since then, XOMA stock has increased by 43.1% and is now trading at $37.60. How were XOMA Royalty's earnings last quarter? XOMA Royalty Corporation (NASDAQ:XOMA) issued its quarterly earnings results on Wednesday, August, 13th. The biotechnology company reported $0.48 EPS for the quarter, topping the consensus estimate of ($0.12) by $0.60. The biotechnology company had revenue of $13.13 million for the quarter, compared to the consensus estimate of $9.39 million. XOMA Royalty had a negative net margin of 27.57% and a positive trailing twelve-month return on equity of 2.63%. Who are XOMA Royalty's major shareholders? Top institutional investors of XOMA Royalty include BVF Inc. IL (21.64%), Opaleye Management Inc. (2.13%), Geode Capital Management LLC (1.70%) and Stonepine Capital Management LLC (1.27%). Insiders that own company stock include Bvf Partners L P/Il, Owen Hughes, Thomas M Burns, Joseph M Limber and Bradley Sitko. View institutional ownership trends. How do I buy shares of XOMA Royalty? Shares of XOMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of XOMA Royalty own? Based on aggregate information from My MarketBeat watchlists, some other companies that XOMA Royalty investors own include American Water Works (AWK), Waste Connections (WCN), AU Optronics (AUOTY), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings8/13/2025Today9/23/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:XOMA CIK791908 Webwww.xoma.com Phone(510) 204-7200Fax510-649-7571Employees10Year Founded1981Price Target and Rating Average Price Target for XOMA Royalty$69.50 High Price Target$104.00 Low Price Target$35.00 Potential Upside/Downside+86.1%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.82 million Net Margins-27.57% Pretax Margin-34.07% Return on Equity2.63% Return on Assets0.97% Debt Debt-to-Equity Ratio1.41 Current Ratio4.88 Quick Ratio4.88 Sales & Book Value Annual Sales$28.49 million Price / Sales15.85 Cash FlowN/A Price / Cash FlowN/A Book Value$6.95 per share Price / Book5.37Miscellaneous Outstanding Shares12,090,000Free Float11,218,000Market Cap$451.62 million OptionableOptionable Beta0.98 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:XOMA) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIs This Nvidia’s Next Big Invention? (Picture Inside)Nvidia gave investors a chance to make more than 150 times their money with its AI chips known as graphic proc...InvestorPlace | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Royalty Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA Royalty With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.